Tropical disease

Venatorx Pharmaceuticals Announces Changes to Executive Leadership

Retrieved on: 
星期四, 五月 16, 2024
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, Patient, Doctor of Philosophy, Pfizer, HIV, Food, FDA, Medication, Entasis, Therapy, Safety, Pyelonephritis, Research, Meropenem, Global health, Acquisition, Acinetobacter baumannii, Urinary tract infection, Pneumonia, Cutis, Food and Drug Administration, Tropical disease, Development, Pharmaceutical industry

Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced today several changes to its executive leadership team.

Key Points: 
  • Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced today several changes to its executive leadership team.
  • Manos Perros, PhD, has been appointed to the Board of Directors as Executive Chairman.
  • Dr. Perros is a distinguished pharmaceutical and biotech executive with an impressive track record that includes more than 25 years in life sciences research and development.
  • Dr. Perros’ appointment follows the resignation of Christopher J. Burns, Ph.D., who has stepped down as Chief Executive Officer and Director of Venatorx Pharmaceuticals.

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
星期二, 五月 7, 2024
FDA, VLA, Bank statement, Fast Track, Research, CHMP, Trial of the century, Biologics license application, Coalition, Profit & Loss, OrbiMed, Lyme disease, Bavarian Nordic, CDC, Notifiable disease, Adolescence, Income tax, Chikungunya, Third party, ACIP, BLA, Licensure, CEPI, PRV, Safety, Travel, Indoor Living, EMA, Marketing, USD, Sale, Tropical disease, EDT, Depreciation, MAA, Profit, Euronext Paris, Zika virus, Epidemic, Adjustment, COGS, Saint-Herblain, COVID-19, Growth, Ageing

Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.

Key Points: 
  • Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.
  • The condensed consolidated interim financial results are available on the Company’s website ( Financial Reports – Valneva ).
  • In the first quarter of 2024, IXIARO®/JESPECT® sales were €16.6 million compared to €17.4 million in the first quarter of 2023.
  • IXIARO®/JESPECT® sales were €16.6 million in the first quarter of 2024 compared to €17.4 million in the first quarter of 2023.

Dr. Peter Hotez Named To TIME's Inaugural TIME100 Health List of the 100 Most Influential People in Global Health this Year

Retrieved on: 
星期四, 五月 2, 2024
American Academy, National academy, Science, Hospital, Tropical medicine, Book, Health, IDSA, Vaccine, TIME, National school, Baylor College of Medicine, Nobel Peace Prize, Texas Children's Hospital, Tropical disease, Corbevax, COVID-19, Baylor University, Global health

The full list and related tributes appear in the May 13, 2024 issue of TIME, available on newsstands on Friday, May 3, and now at time.com/time100health .

Key Points: 
  • The full list and related tributes appear in the May 13, 2024 issue of TIME, available on newsstands on Friday, May 3, and now at time.com/time100health .
  • "I'm grateful for the TIME100 Health 2024 recognition, particularly for our low-cost vaccines for neglected diseases and global health, as well as my efforts to counter rising antivaccine and antiscience activism," said Dr. Hotez.
  • The list recognizes the impact, innovation, and achievement of the world's most influential individuals in health.
  • Dr. Hotez is an elected member of the National Academy of Medicine and American Academy of Arts and Sciences and the author of several books.

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

Retrieved on: 
星期四, 四月 11, 2024
FDA, Tropical disease, PRV, NDA, Food, CDC, HAT, Research, IBN, Trypanosoma brucei, DSM-IV codes, Suramin, Autism spectrum, Pharmaceutical industry

A successful review and approval of the NDA could further qualify the company for a Tropical Disease Priority Review Voucher (PRV).

Key Points: 
  • A successful review and approval of the NDA could further qualify the company for a Tropical Disease Priority Review Voucher (PRV).
  • PaxMedica plans to fund a sustainable global supply chain for PAX-101, and further advance research and clinical trials to address Autism Spectrum Disorder.
  • “This is a very significant milestone for PaxMedica as it endeavors to move PAX-101 towards an NDA submission,” said Howard Weisman, chairman and CEO of PaxMedica.
  • “The long-term vision for PaxMedica is to further clinical investigation of PAX-101 as a treatment for individuals who struggle with Autism Spectrum Disorder.

NFL Star Rob Gronkowski and Anivive Lifesciences Join Congressional Leaders on Capitol Hill to Combat the Rising Threat of Valley Fever

Retrieved on: 
星期二, 十二月 19, 2023
Spore, Pet, Risk, Gronk, Infection, Research, Fungus, FDA, University, Vaccine, Disease, Health, PRV, Human, Congress, Inhalation, Dog, Coccidioidomycosis, Animal, Fungal infection, Climate change, Tropical disease, NFL, Public, Super Bowl, USDA, Coccidioides, Veterinarian, Military personnel, Southwestern United States, Soil

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- On Capitol Hill last Tuesday, NFL Icon and 4-time Super Bowl Champion Rob Gronkowski and Senators Mark Kelly, Kyrsten Sinema, Markwayne Mullin, and Representative David Schweikert led an event focused squarely on the rising challenge of Valley Fever. Intensified by climate change, this fungal infection is not only a burgeoning public health concern in the American Southwest but also a significant economic burden, costing the U.S. healthcare system an estimated $3.9 billion annually.

Key Points: 
  • - Capitol Hill puts Valley fever in the spotlight just in time as Anivive's canine vaccine is under regulatory review.
  • - Congress introduced 4 bills that aim to fast-track the FDA review of Valley fever solutions and authorize $500 million to support fungal disease initiatives.
  • WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- On Capitol Hill last Tuesday, NFL Icon and 4-time Super Bowl Champion Rob Gronkowski and Senators Mark Kelly, Kyrsten Sinema, Markwayne Mullin, and Representative David Schweikert led an event focused squarely on the rising challenge of Valley Fever.
  • Valley Fever, a serious fungal infection caused by the soil-dwelling Coccidioides, results in tens of thousands of human cases each year.

Particles for Humanity Receives Approval to Begin a Study of PFH-VAP in Humans

Retrieved on: 
星期二, 十二月 12, 2023
Vitamin A, Institutional review board, Research, IRB, Mineral, Mulago Foundation, Pregnancy, Principal investigator, University of Wisconsin–Madison, Bill, Multimedia, Malnutrition, Vitamin A deficiency, Humanity, Vitamin, University, Human, Tropical disease, Dietary supplement

The study is designed to confirm that PFH-VAP's improved stability enables more vitamin A to be delivered into the human body after consumption.

Key Points: 
  • The study is designed to confirm that PFH-VAP's improved stability enables more vitamin A to be delivered into the human body after consumption.
  • Particles for Humanity has partnered with the University of Wisconsin-Madison and the Tropical Diseases Research Centre in Zambia to conduct the study as part of its effort to combat vitamin A deficiency (VAD).
  • VAD is a devastating public health problem affecting 190 million children and 19 million pregnant women worldwide.
  • Particles for Humanity transforms early-stage medical technology into products for people living in low and lower-middle income countries.

Particles for Humanity Expands Diversified Funding in Fight Against Vitamin A Deficiency

Retrieved on: 
星期二, 七月 18, 2023
Human, Institutional review board, University, Malnutrition, Vitamin A, Mulago Foundation, Absorption, Melinda French Gates, Tropical disease, University of Wisconsin–Madison, Tablet, Organization, Bill & Melinda Gates Foundation, Humanity, Bill, Pharmaceutical industry, Mulago

CAMBRIDGE, Mass., July 18, 2023 /PRNewswire/ -- Particles for Humanity has closed investments from King Philanthropies and the Mulago Foundation.

Key Points: 
  • CAMBRIDGE, Mass., July 18, 2023 /PRNewswire/ -- Particles for Humanity has closed investments from King Philanthropies and the Mulago Foundation.
  • The funding will be used to test in humans the absorption of vitamin A from PFH-VAP, a stable form of vitamin A palmitate for large-scale food fortification (LSFF).
  • When used to fortify staple foods like wheat flour, sugar, and bouillon, PFH-VAP has the potential to reduce vitamin A deficiency in hundreds of millions of people throughout Africa.
  • To date, Particles for Humanity has raised $20 million in the fight against malnutrition.

Government of Japan Expresses its Pledge of US$200 Million to GHIT Fund/UNDP Replenishment

Retrieved on: 
星期四, 五月 25, 2023
Vaccine, Takeda Pharmaceutical Company, Partnership, Government of Japan, Neglected tropical diseases, Therapy, Shionogi, United Nations, Daiichi Sankyo, Risk management, Merck Group, UNDP, Research, Infection, Global Health Innovative Technology Fund, Bill & Melinda Gates Foundation, Government, Fujifilm, PPP, Climate change, Investment, Tuberculosis, Patient, United Nations Development Programme, Bill, R, Environment, Tropical disease, Malaria, Pharmaceutical industry, Limited, Wellcome

TOKYO, May 25, 2023 /PRNewswire/ -- At the G7 Hiroshima Summit 2023, Prime Minister Fumio Kishida announced the Government of Japan's pledge to contribute US$200 million to the Global Health Innovative Technology Fund (GHIT Fund)/United Nations Development Programme (UNDP). This pledge supports the GHIT Fund's third phase of operations, including investments in research and development (R&D) of drugs, vaccines and diagnostics, utilizing Japan's innovation and expertise to prevent and address infectious diseases such as tuberculosis, malaria and neglected tropical diseases (NTDs), which are highly prevalent in low- and middle-income countries.

Key Points: 
  • In addition to the new contribution from the Government of Japan, support from industry for GHIT's replenishment has increased compared to previous replenishments.
  • Additionally, founding foundation partners Bill & Melinda Gates Foundation and Wellcome will continue to support GHIT.
  • Over the next five years, the GHIT Fund will strive to secure additional support with a total replenishment goal of US$400 million to support operations and investments.
  • This replenishment supports the implementation of "GHIT 3.0," the institution's third five-year plan, as follows.

PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023

Retrieved on: 
星期一, 五月 15, 2023
HAT, Suramin, PRV, Priority review, Spectrum, Tropical disease, Clinical trial, NDA, Coronavirus Scientific Advisory Board, Disorder, Food and Drug Administration Amendments Act of 2007, ASD, Security (finance), FDA, IND, Food, Pharmaceutical industry, Cryptocurrency

Howard Weisman, Chief Executive Officer of PaxMedica, commented, “During the first quarter we’ve continued working hard to advance the ongoing retrospective Phase 3 HAT-301 trial and we continue to expect to announce top line results in the second half of 2023.

Key Points: 
  • Howard Weisman, Chief Executive Officer of PaxMedica, commented, “During the first quarter we’ve continued working hard to advance the ongoing retrospective Phase 3 HAT-301 trial and we continue to expect to announce top line results in the second half of 2023.
  • PaxMedica had 13,920,234 million common shares issued and outstanding at March 31, 2023.
  • Subsequent to quarter end, the Company received proceeds of approximately $1.1 million from the issuance of approximately 0.6 million shares of the Company’s common stock.
  • For PaxMedica’s complete financial results for the three-month period ended March 31, 2023, see the Company’s Quarterly Form 10-Q that will be filed with the Securities and Exchange Commission on May 15, 2023.

GHIT Fund Secures USD 24 Million Pledge From Bill & Melinda Gates Foundation Over Three Years

Retrieved on: 
星期三, 五月 10, 2023
Vaccine, Poverty, Partnership, Neglected tropical diseases, Government of Japan, United Nations, Life, Infection, Global Health Innovative Technology Fund, UNDP, Global health, Research, Risk, Bill & Melinda Gates Foundation, PPP, JPY, Developed country, Tuberculosis, United Nations Development Programme, Bill, Health, Hunger, Tropical disease, Malaria, Pharmaceutical industry, Wellcome

"The Bill & Melinda Gates Foundation has been supporting the GHIT Fund as a critical partner since its inception.

Key Points: 
  • "The Bill & Melinda Gates Foundation has been supporting the GHIT Fund as a critical partner since its inception.
  • Katey Owen, director of neglected tropical diseases and director, vaccine development, Bill & Melinda Gates Foundation, said: "Over the past nine years, our relationship with GHIT has evolved and expanded.
  • The GHIT Fund is a Japan-based international public-private partnership fund (PPP) that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP).
  • The Bill & Melinda Gates Foundation is a US-based foundation established in 2000.